Neurofibromatosis Type I: Consensus on Current Terminology for Neurofibromas, as a Basis for Recommendations on the Use of MEK Inhibitors

LAURA BALDINO, JOHANNES A. KOEPPEN, JOSEF KAMMERMEIER, ISABEL GUGEL, INKA RISTOW, CHRISTIAN HAGEL, JENS PANSE, CATENA KRESBACH, REINHARD E. FRIEDRICH, SAID C. FARSCHTSCHI, THORSTEN ROSENBAUM, ANDREAS KURTZ, PABLO HERNAIZ-DRIVER, DIETER KAUFMANN, MARTIN ZENKER, MARTIN U. SCHUHMANN, BRIGITTE C. WIDEMANN, STEFFEN K. ROSAHL, FRANZISKA ALT, HILDEGARD KEHRER-SAWATZKI, UTE BAEZNER, DANIEL TIPPNER, ANJA HARDER, VICTOR-F. MAUTNER

Open source

DOI: 10.21873/anticanres.18332
Published: 2026-08-31
Container: Anticancer Research
Publisher: International Institute of Anticancer Research
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.21873/anticanres.18332,
  title = {Neurofibromatosis Type I: Consensus on Current Terminology for Neurofibromas, as a Basis for Recommendations on the Use of MEK Inhibitors},
  author = {LAURA BALDINO and JOHANNES A. KOEPPEN and JOSEF KAMMERMEIER and ISABEL GUGEL and INKA RISTOW and CHRISTIAN HAGEL and JENS PANSE and CATENA KRESBACH and REINHARD E. FRIEDRICH and SAID C. FARSCHTSCHI and THORSTEN ROSENBAUM and ANDREAS KURTZ and PABLO HERNAIZ-DRIVER and DIETER KAUFMANN and MARTIN ZENKER and MARTIN U. SCHUHMANN and BRIGITTE C. WIDEMANN and STEFFEN K. ROSAHL and FRANZISKA ALT and HILDEGARD KEHRER-SAWATZKI and UTE BAEZNER and DANIEL TIPPNER and ANJA HARDER and VICTOR-F. MAUTNER},
  year = {2026},
  journal = {Anticancer Research},
  doi = {10.21873/anticanres.18332},
  url = {https://doi.org/10.21873/anticanres.18332}
}

RIS

TY  - JOUR
TI  - Neurofibromatosis Type I: Consensus on Current Terminology for Neurofibromas, as a Basis for Recommendations on the Use of MEK Inhibitors
AU  - LAURA BALDINO
AU  - JOHANNES A. KOEPPEN
AU  - JOSEF KAMMERMEIER
AU  - ISABEL GUGEL
AU  - INKA RISTOW
AU  - CHRISTIAN HAGEL
AU  - JENS PANSE
AU  - CATENA KRESBACH
AU  - REINHARD E. FRIEDRICH
AU  - SAID C. FARSCHTSCHI
AU  - THORSTEN ROSENBAUM
AU  - ANDREAS KURTZ
AU  - PABLO HERNAIZ-DRIVER
AU  - DIETER KAUFMANN
AU  - MARTIN ZENKER
AU  - MARTIN U. SCHUHMANN
AU  - BRIGITTE C. WIDEMANN
AU  - STEFFEN K. ROSAHL
AU  - FRANZISKA ALT
AU  - HILDEGARD KEHRER-SAWATZKI
AU  - UTE BAEZNER
AU  - DANIEL TIPPNER
AU  - ANJA HARDER
AU  - VICTOR-F. MAUTNER
PY  - 2026
JO  - Anticancer Research
DO  - 10.21873/anticanres.18332
UR  - https://doi.org/10.21873/anticanres.18332
ER  -

APA

BALDINO, L., KOEPPEN, J. A., KAMMERMEIER, J., GUGEL, I., RISTOW, I., HAGEL, C., PANSE, J., KRESBACH, C., FRIEDRICH, R. E., FARSCHTSCHI, S. C., ROSENBAUM, T., KURTZ, A., HERNAIZ-DRIVER, P., KAUFMANN, D., ZENKER, M., SCHUHMANN, M. U., WIDEMANN, B. C., ROSAHL, S. K., ALT, F., KEHRER-SAWATZKI, H., BAEZNER, U., TIPPNER, D., HARDER, A., & MAUTNER, V. (2026). Neurofibromatosis Type I: Consensus on Current Terminology for Neurofibromas, as a Basis for Recommendations on the Use of MEK Inhibitors. Anticancer Research. https://doi.org/10.21873/anticanres.18332

Source records

crossref · retrieved 2026-09-25T03:00:05.318Z